- Report
- February 2026
- 250 Pages
Global
From €4017EUR$4,490USD£3,436GBP
- Report
- February 2026
- 250 Pages
Global
From €4017EUR$4,490USD£3,436GBP
- Report
- February 2026
- 250 Pages
Global
From €4017EUR$4,490USD£3,436GBP
- Report
- May 2026
- 185 Pages
Global
From €4026EUR$4,500USD£3,443GBP
- Report
- May 2026
- 185 Pages
Global
From €4026EUR$4,500USD£3,443GBP
- Report
- May 2026
- 177 Pages
Global
From €4026EUR$4,500USD£3,443GBP
- Report
- January 2026
- 180 Pages
Global
From €4026EUR$4,500USD£3,443GBP
- Report
- January 2026
- 181 Pages
Global
From €4026EUR$4,500USD£3,443GBP
- Clinical Trials
- April 2026
- 180 Pages
Global
From €1790EUR$2,000USD£1,530GBP
- Clinical Trials
- April 2026
- 450 Pages
Global
From €4474EUR$5,000USD£3,826GBP
- Drug Pipelines
- April 2026
- 280 Pages
Global
From €2684EUR$3,000USD£2,295GBP
- Report
- July 2026
- 70 Pages
Global
From €4250EUR$4,750USD£3,635GBP
- Report
- May 2026
- 140 Pages
Global
From €4250EUR$4,750USD£3,635GBP
- Report
- May 2026
- 140 Pages
Global
From €4250EUR$4,750USD£3,635GBP
- Report
- March 2026
- 400 Pages
Global
From €4428EUR$4,949USD£3,787GBP
- Report
- April 2026
- 305 Pages
Global
From €2237EUR$2,500USD£1,913GBP
- Report
- January 2026
- 286 Pages
Global
From €2237EUR$2,500USD£1,913GBP
- Report
- May 2026
- 150 Pages
Global
From €2415EUR$2,699USD£2,065GBP
- Report
- July 2026
- 160 Pages
Global
From €3713EUR$4,150USD£3,175GBP
- Report
- July 2026
- 160 Pages
Global
From €3713EUR$4,150USD£3,175GBP

The GLP-1 Receptor Agonist market is a subset of the Central Nervous System Drugs market. GLP-1 Receptor Agonists are drugs that act on the GLP-1 receptor, a protein found in the brain and other parts of the body. These drugs are used to treat a variety of conditions, including obesity, type 2 diabetes, and depression. GLP-1 Receptor Agonists work by stimulating the release of insulin and other hormones, which can help regulate blood sugar levels and reduce appetite.
GLP-1 Receptor Agonists are typically administered as injections, and are often used in combination with other medications. They are generally well-tolerated, with few side effects. However, they can be expensive, and may not be covered by insurance.
Some companies in the GLP-1 Receptor Agonist market include Novo Nordisk, Eli Lilly, AstraZeneca, and Sanofi. Show Less Read more